byMaria Holyanova

This week, researchers published a study in Cancer, a journal of the American Cancer Society, evaluating the safety, feasibility, and efficacy of psilocybin-assisted group therapy for the treatment of major depressive disorder (MDD) in patients diagnosed with cancer in a Phase 2 open-label clinical trial. The researchers recruited 30 MDD patients with curable and non-curable cancer and administered a single 25 mg dose of psilocybin, with 3–4 patients receiving their dose simultaneously.

On December 12, MAPS Public Benefit Corporation announced their submission of New Drug Application (NDA) to the FDA for their MDMA-assisted therapy for PTSD program, marking a historic moment for the mental health field. This is a significant milestone for the psychedelics industry.

On December 12, MAPS Public Benefit Corporation announced their submission of New Drug Application (NDA) to the FDA for their MDMA-assisted therapy for PTSD program, marking a historic moment for the mental health field. The Multidisciplinary Association for Psychedelic Studies (MAPS) has always been one of the organizations tirelessly working to knock down the foundational bricks of the War on Drugs, as laid out by President Richard Nixon.